|Assessment Status||Rapid Review Complete|
|Indication||Deucravacitinib is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.|
|Rapid review commissioned||01/06/2023|
|Rapid review completed||27/06/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that deucravacitinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.